Mylan NV
Shares of the company, which on Tuesday also disclosed a warning letter it received from the FDA earlier this month, fell nearly 2 percent to $33.91 after the bell.
The news comes a day after the European Union authorities stepped in to effectively ban sales of valsartan made by an India-based Mylan unit after some batches were found to contain the same impurity, N-nitrosodiethylamine (NDEA).
TRENDING NOW

PM Modi arrives at party headquarters after BJP secures win in Rajasthan, is leading in MP and Chhattisgarh

Telangana Election Result 2023: Revanth Reddy, the man who led Congress' dramatic turnaround in southern state

Assembly Election 2023 Results Update: MPs who win assembly polls have to quit one seat in 14 days, says Expert

India vs Australia 5th T20I Free Live Streaming: When and Where to watch IND VS AUS T20I series Match LIVE on Mobile Apps, TV, Laptop, Online

Telangana Election Result 2023: Congress wins from Jukkal and Medak, BRS nets Quthbullapur constituency

Assembly Election 2023 Results Update: PM Modi congratulates voters for Assembly wins in MP, Chhattisgarh, Rajasthan
Mylan said on Tuesday it would recall at least 15 lots of medicines containing valsartan distributed in the United States between March 2017 and November 2018 and manufactured by units Mylan Pharmaceuticals and Mylan Laboratories.
Over the past year, global health authorities have been cracking down on valsartan and drugs containing the substance as an active ingredient after several batches were found to contain NDEA and a second possible carcinogen, N-nitrosodimethylamine (NDMA).
The U.S. FDA last month halted imports of drug ingredients or medicines containing ingredients produced at a factory belonging to a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals .
Huahai had recalled the tainted product from consumers in the United States in July.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
05:30 am